Author details

Full Name

Richard B Pearson

Affiliation

ORCID

Career Start Year

1982

Papers

137

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37188662	Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments.	Nat Commun	2023
35232962	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma.	Nat Commun	2022
35758651	Cystathionine-Î²-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation.	eLife	2022
34413130	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.	Mol Cancer Ther	2021
33512431	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.	Blood	2021
33173151	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.	Br J Cancer	2021
34462428	Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy.	Signal Transduction and Targeted Therapy	2021
34750583	The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function.	Nat Cell Biol	2021
31285545	A functional genetic screen defines the AKT-induced senescence signaling network.	Cell Death Differ	2020
32171687	Oncogene-induced senescence: From biology to therapy.	Mechanisms of Ageing and Development	2020
32651259	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.	Cancer Res	2020
33235908	CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer.	Molecular and Cellular Oncology	2020
32945574	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.	EMBO J	2020
32719798	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.	Frontiers in Cell and Developmental Biology	2020
31439820	Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.	Proc Natl Acad Sci U S A	2019
31092402	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.	Cancer Discov	2019
30701204	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.	Commun Biol	2019
31488714	Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.	Proceedings of the National Academy of Sciences of the United States of America	2019
30803482	Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer.	eLife	2019
30670779	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.	Oncogene	2019
29238073	Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.	Cell Death and Differentiation	2018
30266954	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.	Nat Commun	2018
30050925	Cystathionine -Synthase in Physiology and Cancer.	BioMed Research International	2018
30049486	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.	Eur Urol	2018
29669917	Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers.	Proceedings of the National Academy of Sciences of the United States of America	2018
29337961	How the evolution of multicellularity set the stage for cancer.	British Journal of Cancer	2018
29243224	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naÃ¯ve melanoma but not after the development of BRAF inhibitor resistance.	Int J Cancer	2018
27663592	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.	Clin Cancer Res	2017
28484005	Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors.	Proceedings of the National Academy of Sciences of the United States of America	2017
28283481	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.	Blood	2017
28212321	Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.	Genes (Basel)	2017
27989772	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription.	Gene	2017
28117679	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.	International Journal of Molecular Sciences	2017
27552145	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence.	Assay Drug Dev Technol	2016
27391441	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.	Oncotarget	2016
27385002	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.	Oncotarget	2016
27486174	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.	Clin Cancer Res	2016
26490423	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.	Cancer Discov	2016
24632621	PR55Î±-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.	Oncogene	2015
25464032	The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.		2015
25790252	Unexpected role of CDK4 in a G2/M checkpoint.	Cell Cycle	2015
25452314	A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.	Genome Research	2015
25447905	Regulation of rDNA transcription in response to growth factors, nutrients and energy.	Gene	2015
25740609	PR55Î±-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.	Oncogene	2015
25852062	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.	Mol Cancer Ther	2015
26215099	S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila.	Cellular Signalling	2015
26286024	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.	Sci Signal	2015
24658684	Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.	PLoS One	2014
24389329	Targeting the nucleolus for cancer intervention.		2014
24495407	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment Cell Melanoma Res	2014